Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449200 | 0.94 | LMNA (0.33) | LMNAHSD17B10 | |
| SCHEMBL27734679 | 0.92 | LMNA (0.32) | LMNAHSD17B10 | |
| SCHEMBL27745506 | 0.92 | LMNA (0.32) | LMNAHSD17B10 | |
| SCHEMBL28835000 | 0.83 | GAA (0.32) | GAA | |
| SCHEMBL3077229 | 0.81 | LMNA (0.35) | LMNAHSD17B10GAAALOX15 | |
| SCHEMBL27535729 | 0.81 | CYP4F2 (0.40) | LMNAHSD17B10GAAALOX15 | |
| SCHEMBL16244342 | 0.81 | LMNA (0.44) | LMNAHSD17B10ALOX15 | |
| SCHEMBL28835002 | 0.81 | GAA (0.31) | GAA | |
| SCHEMBL3203563 | 0.79 | CYP4F2 (0.43) | LMNAHSD17B10GAAALOX15 | |
| SCHEMBL3257031 | 0.79 | LMNA (0.34) | LMNAHSD17B10GAAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702452-B2 | Process for making arylomycin ring analogs | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220056078-A1 | PROCESS FOR MAKING ARYLOMYCIN RING ANALOGS | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11192924-B2 | Process for making arylomycin ring analogs | GENENTECH, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3601240-B1 | PROCESS FOR MAKING ARYLOMYIN RING ANALOGS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| CN-107428765-B | Pyridazinone macrocyclic compounds used as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20200255476-A1 | PROCESS FOR MAKING ARYLOMYCIN RING ANALOGS | GENENTECH, INC. (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3601240-A1 | PROCESS FOR MAKING ARYLOMYIN RING ANALOGS | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183198-A1 | PROCESS FOR MAKING ARYLOMYIN RING ANALOGS | GENENTECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| CN-107428765-A | Pyridazinone macrocyclic compounds used as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-103443077-B | TRPM8 receptor antagonist | DOMPE' S.P.A. (IT) | 2016-05-18 | — | — | CN | disclosed |
| CN-101123962-A | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS INC (US) | 2008-02-13 | — | — | CN | disclosed |
| CN-101052397-A | 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2007-10-10 | — | — | CN | disclosed |
| CN-101006092-A | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and therapeutic agents using the same | PFIZER (US) | 2007-07-25 | — | — | CN | disclosed |
| CN-1946680-A | Non-nucleoside reverse transcriptase inhibitors | HOFFMANN LA ROCHE (CH) | 2007-04-11 | — | — | CN | disclosed |
| CN-1917873-A | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| WO-2007003525-A2 | CYCLIC ANILINO-PYRIDINOTRIAZINES AS GSK-3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-11 | — | — | WO | disclosed |
| CN-1856305-A | Pyridine derivatives and their use as urotensin II antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-01 | — | — | CN | disclosed |
| CN-1838953-A | Phosphatidylinositol 3-kinase (PI3) inhibitor 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives for the treatment of inflammatory airway diseases | NOVARTIS AG (CH) | 2006-09-27 | — | — | CN | disclosed |
| CN-1708476-A | Novel amide compounds having MCH-antagonistic action and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-12-14 | — | — | CN | disclosed |
| CN-1617869-A | 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2005-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702452-B2 | Process for making arylomycin ring analogs | RRS1, GLRA1, MRPL21 | LMNA 2760/4885HSD17B10 918/4885GAA 1898/4885 |
| US-11192924-B2 | Process for making arylomycin ring analogs | RRS1, GLRA1, MRPL21 | LMNA 2760/4885HSD17B10 918/4885GAA 1898/4885 |
| US-20220056078-A1 | PROCESS FOR MAKING ARYLOMYCIN RING ANALOGS | RRS1, GLRA1, MRPL21 | LMNA 2760/4885HSD17B10 918/4885GAA 1898/4885 |
| US-20200255476-A1 | PROCESS FOR MAKING ARYLOMYCIN RING ANALOGS | RRS1, GLRA1, MRPL21 | LMNA 2760/4885HSD17B10 918/4885GAA 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.